Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

HIV And HCV adherence and treatment outcomes among people who inject drugs receiving opioid agonist therapy

Bibliographic Data

ID19443625
AuthorsHadi J Minhas (0000-0002-0985-266X, Department of Medicine, Albany Medical Center/Albany Medical College, Albany, NY, USA), Matthew J Akiyama (0000-0003-4290-3083, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA), Brianna L Norton (0000-0002-8287-2245, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA), Moonseong Heo (0000-0001-7711-1209, Clemson University), Julia H Arnsten (0000-0002-7741-1567, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA), Alain H Litwin (0000-0002-6717-0288, University of South Carolina School of Medicine – Greenville, Greenville, SC, USA, corresponding author)
Year2022
Volume34
Issue10
Pages1229-1233
Publication date2022-10-03
Open AccessNo
TypeARTICLE
VenueAIDS Care (JOURNAL)
Journal identifiersISSN: 0954-0121 • E-ISSN: 1360-0451
PublisherInforma UK Limited (PUBLISHER • GB)
DOI10.1080/09540121.2021.1973659
PMID34533062
OpenAlexW3201380380
LanguageEN
References cited19

Among people who inject drugs (PWID), 60% have HCV and 50–90% of HIV-infected PWID are co-infected with HCV. Data comparing adherence to direct-acting antiviral (DAA) therapy among HCV mono-infected and HIV/HCV co-infected PWID is limited. The impact of HCV treatment initiation on HIV antiretroviral therapy (ART) adherence is also poorly understood. We assessed DAA adherence in HCV mono-infected and HIV/HCV co-infected PWID and examined changes in ART adherence and HIV outcomes following HCV treatment. Study was conducted in three Medication for Opioid use Disorder (MOUD) programs in Bronx, New York. HCV treatment adherence was measured using electronic blister packs. 2-week DAA adherence rates were compared and controlled for study arm, psychiatric illness and alcohol intoxication within the past 30 days. ART adherence was measured using participant self-report and dichotomized to “excellent” or “other”. ART adherence, CD4 count, and HIV viral load were identified six months prior to, during, and six months after HCV treatment. Statistical significance was assessed with mixed-effects regression linear or logistic models. Overall DAA adherence rates among HCV mono-infected and HIV/HCV co-infected PWID were 74% (95% CI=71–78%) and 76% (95%CI=70–83%), respectively (p=.55). There were no significant changes in ART adherence, CD4 counts, or HIV viral loads prior to, during, or after HCV treatment. This is the first study assessing the impact of DAA therapy on ART adherence and HIV treatment outcomes among PWID. It is one of the first to compare DAA adherence among HCV and HIV/HCV co-infected PWID. Our data demonstrate no significant difference in DAA adherence and no significant impact of HCV treatment on ART adherence or HIV outcomes

Coinfection · Drug · Hepatitis C · Heroin · Logistic regression · Psychiatry · Viral load · Hepatitis C virus research · HIV/AIDS drug development and treatment · HIV/AIDS Research and Interventions · Medicine · Immunology · Internal Medicine

Highly citedNo

Tools

Open DOIOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae